Navigation Links
The Most Advanced Solution for the Reduction of Stretch Marks Based on TriPollar(R) Technology Presented at the Upcoming EADV Congress
Date:10/1/2009

TEL AVIV, Israel, October 1 /PRNewswire/ -- Dr. Worophong Manuskiatti has been invited to present results of his study "Treatment of striae distensae in skin phototypes IV-V with a TriPollar radiofrequency device" in the upcoming meeting of the European Academy of Dermatology and Venereology (EADV) Conference held on October 7-10, 2009 in Berlin, Germany.

The oral presentation will take place on Thursday, October 8, 2009 at 10:15-11:45 in session FC 2 Lasertherapy, room 43.

In the clinical study, seventeen females with stretch marks underwent six weekly treatments with the apollo(TM) device- Pollogen's latest aesthetic solution based on TriPollar(TM) technology. Results showed that at one week after the final (sixth) treatment, 38.2% and 11.8% of the patients were assessed to have 25-50% and 51-75% improvement in the appearance of their stretch marks, respectively. The long term effect of the treatment was confirmed during the 6 weeks follow up which showed that a higher percentage of the patients were rated to have improvement of their stretch marks, including 26.5% and 5.9% showing 51-75% and >75% improvement, respectively None of the participants were rated as having no improvement in their clinical appearance of stretch marks. Patient satisfaction was also measured and 65% of patients reported that they were very satisfied with the treatment, 23% were satisfied and 12% were slightly satisfied.

Full study results have recently been published in the online edition of the Journal of Dermatological Treatment.

Dr. Manuskiatti commented: "Stretch marks are a skin condition that has been traditionally very challenging to treat. The study confirms that collagen remodeling induced by RF heating is an effective mechanism for improving the surface appearance of stretch marks. I am delighted that TriPollar(R) technology delivered significant measurable results that were maintained during the long term follow-up examination and that patients reported a pain free and pleasant experience".

Company Founder and CEO, Dr. Zion Azar stated: "Pollogen is delighted to have results of its study presented at the upcoming EADV congress. TriPollar offers a proven alternative to invasive treatments and it is important that dermatologists are exposed to leading technologies and solutions that they can offer their patients. A primary audience for this treatment is post-pregnancy women who would like to eliminate abdominal stretch marks safely, effectively and in a completely painless and fast procedure.

About Pollogen:

Pollogen Ltd. develops, manufactures and markets professional medical aesthetic devices, powered by the TriPollar(TM) 3rd generation Radio Frequency (RF) technology. Invented and perfected by Pollogen, proprietary TriPollar(TM) technology powers a full line of clinically-proven, non-invasive and non-surgical treatment platforms for wrinkles, cellulite, circumference reduction and skin tightening. The flagship aesthetic devices, apollo(TM) and regen(TM) offer customers clinically-proven, safe and effective anti-aging beauty treatments that deliver immediate and long-lasting results. To learn more, please visit the Pollogen website at http://www.pollogen.com

    Contact:
    Name: Abigail Marks
    Tel: +972-54-244-5807
    E-mail: abigail_m@pollogen.com


SOURCE Pollogen Ltd.


'/>"/>
SOURCE Pollogen Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... -- Two Bayer U.S. Pharmaceutical leaders received top awards from ... th Woman of the Year event ... mission of furthering the advancement and impact of women ... Powell-Steffen , senior director of brand activation and inside ... Howe , a regional business manager for New England ...
(Date:5/11/2017)... 2017  Thornhill Research Inc. ( Toronto, ... $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the ... Corporation (CCC) ( Ottawa, Ontario, Canada ... general anesthesia to patients requiring emergency medical procedures ... Marine Corps have been a longtime partner with ...
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, pharmaceutical, ... and 31st at The Four Seasons Hotel Boston. , The Boston CEO ... offering exclusive access to key decision makers who influence deal making and investment. ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, ... NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI ... diagnostic device operations. With this platform, initializing devices and importing studies are just ...
(Date:5/26/2017)... ... May 26, 2017 , ... via seating ... mesh back 24/7 task chair specifically designed for clinical areas. Genie Copper Mesh ... to partner with Cupron® to provide customers with a game changing chair that ...
(Date:5/26/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... being discussed by President Donald Trump and the rest of the world. Donald Trump ... peace talks in the continuous battle between Israel and Palestine. The world’s eyes are ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral ... new, informational blog post on insurance options. If a Bay Area patient has to ... save time and money. Visiting an in-network provider for a second opinion can ensure ...
Breaking Medicine News(10 mins):